Alternative Antibiotics for Syphilis

Summary

The Trep-AB clinical trial will test the efficacy of an investigational neuropenetrative drug, Linezolid (LZD), compared to standard treatment, Benzathine penicillin G (BPG), for early syphilis in humans. The overarching idea of the work proposed herein is to investigate the use of LZD to treat syphilis, conducting a randomized controlled clinical trial to evaluate this new indication of a known antibacterial agent.

Timeline

Start

2021-10-14

Primary completion

2026-04-15

Completion

2026-04-15

Outcome

Missed primary endpoint

paper treatment difference -29·6, 95% CI -50·5 to -8·8), which did not meet the non-inferiority criterion. PMID 38211601 ↗

Publications

• Ubals M, Nadal-Baron P, Arando M, Rivero A, Mendoza A, Descalzo Jorro V, Ouchi D, Perez-Mana C, Alvarez M, Alemany A, Hoyos-Mallecot Y, Nunley E, Lieberman NAP, Greninger AL, Galvan-Casas C, Suner C, G-Beiras C, Paredes R, Rodriguez-Gascon A, Canut A, Garcia-Patos V, Farre M, Marks M, Giacani L, Vall-Mayans M, Mitja O. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2024 Apr;24(4):404-416. doi: 10.1016/S1473-3099(23)00683-7. Epub 2024 Jan 8.

Drugs

Indications